Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 18/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | GPR6 | P46095 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27769032 | 0.87 | GPR119 (0.65) | GPR119CYP2C9GPR6 | |
| SCHEMBL5189169 | 0.85 | GPR119 (0.59) | GPR119CYP2C9 | |
| SCHEMBL388899 | 0.83 | GPR119 (0.68) | GPR119CYP2C9 | |
| SCHEMBL2403676 | 0.83 | GPR119 (0.61) | GPR119CYP2C9 | |
| SCHEMBL391797 | 0.83 | GPR119 (0.64) | GPR119CYP2C9 | |
| SCHEMBL5189012 | 0.82 | GPR119 (0.58) | GPR119CYP2C9GPR6 | |
| SCHEMBL2786447 | 0.82 | GPR119 (0.79) | GPR119CYP2C9 | |
| SCHEMBL5046636 | 0.82 | GPR119 (0.59) | GPR119CYP2C9GPR6 | |
| SCHEMBL1899893 | 0.81 | GPR119 (0.63) | GPR119CYP2C9GPR6 | |
| SCHEMBL390199 | 0.81 | GPR119 (0.62) | GPR119CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758565-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL | Arena Pharmaceuticals, Inc. (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2006076231-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL | ARENA PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |